NASDAQ:FULC
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$60.4M, and the diluted share count rose 2.2%.Summary generated from Fulcrum Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−25.3%
Debt / equityn/a
Free cash flow−$60.4M
FCF marginn/a
Share count change+2.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 19 | 6 | 3 | 80 | 0 |
| Operating income | −81 | −113 | −111 | −22 | −85 |
| Net income | −81 | −110 | −97 | −10 | −75 |
| Free cash flow | −80 | −99 | −91 | −2 | −60 |
Recent filings
- 8-KEntry into a material agreement
Aug 17, 2026 - 8-KDirector or officer change
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 4Insider transaction report
Jul 20, 2026 - 4Insider transaction report
Jul 15, 2026 - 8-KResults of a shareholder vote
Jun 25, 2026 - 8-KDirector or officer change
Jun 11, 2026 - 8-KCosts of exit or disposal activities
Jun 4, 2026